Search

Displaying results 1831 - 1840 of 2420 in total
  1. Drug

    Nafimidone

    go.drugbank.com/drugs/DB20780
    Experimental

    Nafimidone is a small molecule drug. Nafimidone has a monoisotopic molecular weight of 236.09 Da.

    Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors
  2. Drug

    Fantofarone

    go.drugbank.com/drugs/DB20875
    Experimental

    Fantofarone is a small molecule drug. Fantofarone has a monoisotopic molecular weight of 550.25 Da.

    Categories: P-glycoprotein inhibitors
  3. Drug

    Oxeclosporin

    go.drugbank.com/drugs/DB21134
    Experimental

    Oxeclosporin is a small molecule drug. The usage of the INN stem '-(clo)sporin' in the name indicates that Oxeclosporin is a cyclosporine derivative. Oxeclosporin has a monoisotopic molecular weight of 1261.86 Da.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  4. Drug

    Befetupitant

    go.drugbank.com/drugs/DB21149
    Experimental

    The usage of the INN stem '-pitant' in the name indicates that Befetupitant is a neurokinin NK1​ (substance P) receptor antagonist. Befetupitant has a monoisotopic molecular weight of 565.22 Da.

  5. Drug

    Oveporexton

    go.drugbank.com/drugs/DB21680
    Approved

    Oveporexton is an orally administered orexin receptor 2 (OX2R) agonist used to treat narcolepsy type 1 (NT1). NT1 is caused by the loss of orexin neuropeptide signaling, and oveporexton works by selectively activating OX2R to restore thi...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  6. Drug

    Fosrolapitant

    go.drugbank.com/drugs/DB21723
    Investigational

    The usage of the INN stem '-pitant' in the name indicates that Fosrolapitant is a neurokinin NK1​ (substance P) receptor antagonist. Fosrolapitant has a monoisotopic molecular weight of 654.16 Da.

  7. Drug

    Milsaperidone

    go.drugbank.com/drugs/DB24348
    ApprovedInvestigational

    Milsaperidone is an atypical antipsychotic agent that rapidly interconverts to iloperidone in vivo. Atypical antipsychotic agents work by blocking the D2 dopamine and serotonin receptor signalling pathways. Similarly, milsaperidone acts ...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  8. Drug

    Peginterferon alfa-2a

    go.drugbank.com/drugs/DB00008
    ApprovedInvestigational

    Peginterferon alfa-2a is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus ...

    Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 Enzyme Inhibitors
  9. Drug

    Interferon alfa-n1

    go.drugbank.com/drugs/DB00011
    ApprovedWithdrawn

    Interferon alfa-n1 consists of purified, natural (n is for natural) alpha interferon subtypes, at least two of which are glycosylated. This differs from recombinant alpha interferons, which are individual non-glycosylated proteins produc...

    Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 Enzyme Inhibitors
  10. Drug

    Interferon alfa-n3

    go.drugbank.com/drugs/DB00018
    Approved

    Purified, natural (n is for natural) human interferon alpha proteins (consists of 3 forms or polymorphisms including 2a, 2b and 2c). 166 residues, some are glycosylated (MW range from 16 kD to 27 kD).

    Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 Enzyme Inhibitors